CELL THERAPY FOR THE TREATMENT OF SPHINCTER DYSFUNCTIONS

Description

Fecal incontinence (FI) is a type of sphincter deficiency disorder that consists in disabling condition for affected patients that translates into a significant deterioration in quality of life, social isolation and depressive symptoms.
The current treatment for patients with damaged sphincters is surgical repair. The observed problem is that the success rate is relatively moderate after the procedure. It has been associated with high morbidity, perioperative complications and a high failure rate.
Through preclinical and clinical trials, cell therapy treatment is being evaluated, although the results obtained are promising, the procedure has room for improvement, since there is no certainty that the injected cells will remain at the injection site long enough to regenerate the affected tissue, and the ratio still needs to be improved. cost-effectiveness of treatment.
This invention has developed a treatment based on cell therapy, in which the characteristics and composition of the cell suspension have improved the therapeutic effect, increasing the regeneration of injured muscle tissue.

Advantages

This invention have the following advantages:

Due to the composition of the treatment developed, a better regeneration, innervation and vascularization of the damaged muscle tissue is obtained, with a more satisfactory long-term projection.
The cost-effectiveness of treatment is improved.
The treatment developed maintains the cells at the injection site long enough and in sufficient quantities for the positive evolution of IF.

Uses and Applications

The invention belong to the field of regenerative medicine and cell therapy, and specifically refers to the treatment of sphincter deficiencies.
Today, sphincter deficiency disorders are associated with a significant deterioration in quality of life, social isolation and depressive symptoms.The present invention solves this problem, since it makes it possible to provide a new pharmacological treatment based on cell therapy for the treatment of disorders due to sphincter deficiency, specifically for fecal incontinence.

Keywords

Sectors

Areas

Applicants

UNIVERSIDAD DE MÁLAGA, JUNTA DE ANDALUCÍA. CONSEJERÍA DE SALUD. SERVICIO ANDALUZ DE SALUD., UNIVERSIDAD DE SEVILLA

Inventors

LAURA LEYVA FERNÁNDEZ, FERNANDO DE LA PORTILLA DE JUAN, ANTONIO RODRÍGUEZ ACOSTA, CECILIA ARIANA FRECHA, JESÚS CHAPARRO GARCÍA, RAQUEL MUÑOZ FERNÁNDEZ, RAFAEL MALDONADO SÁNCHEZ

Filing Date

24/09/2021 

Protection Level: Worldwide (PCT countries)

Processing Status: Wordwide (PCT countries) protection application